Ariadne Genomics, Inc., today announced that UCB (Euronext: UCB) has licensed its PathwayStudio® software to support early stages of the drug discovery process - target identification and biomarker research.
Ariadne Genomics, Inc., today announced that UCB (Euronext: UCB) has licensed its PathwayStudio® software to support early stages of the drug discovery process - target identification and biomarker research.